#Inflectra copay assistance free#

Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C. Monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output in patients at risk of developing acute renal failure. In case of hypersensitivity, discontinue GAMUNEX-C infusion immediately and institute appropriate treatment. Severe hypersensitivity reactions may occur with IVIG products, including GAMUNEX-C. It is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity. GAMUNEX-C is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose.

Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs.

Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IVIG) products in predisposed patients. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Ensure adequate hydration in patients before administration. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Thrombosis may occur in the absence of known risk factors. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur with immune globulin products, including GAMUNEX-C. GAMUNEX ®-C (immune globulin injection, 10% caprylate/chromatography purified) is indicated for the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older, idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Grifols reserves the right to change or discontinue this program at any time without notice.

This program is only valid for residents of the United States, excluding Puerto Rico and other US territories.

#Inflectra copay assistance free#

Offer limited to outpatient IG treatment and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, or other offer. Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider. To be eligible, patients must 1) be starting or receiving treatment with (and have a current prescription for) GAMUNEX-C with an ICD9 or ICD10, as applicable of a chronic inflammatory demyelinating polyneuropathy (CIDP) or primary immunodeficiency disease (PIDD) and 2) have commercial insurance that covers medication costs for GAMUNEX-C treatment and allows for copay/coupon assistance. Nonmedication expenses, such as ancillary supplies or administration-related costs, are not eligible. Eligible costs include deductible, copayment, and coinsurance costs for GAMUNEX-C medication. This coupon program provides a maximum benefit of $10,000 for eligible out-of-pocket costs available over a calendar year period. *This manufacturer coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law. TERMS AND CONDITIONS FOR COPAY ASSISTANCE PROGRAM